Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 133
Selected: 0
NCT IDTitle
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT02586610Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
NCT02582749Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
NCT00216216Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
NCT03502746Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
NCT01732107Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
NCT02500121Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
NCT01186458Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT04364048Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
NCT00234494Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
NCT07471841Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
NCT00216164Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04610684Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
NCT04690855A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT00216203Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
NCT03557918Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
NCT03960151Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT06503614A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT01624493BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
NCT00860158Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
NCT02499952Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
NCT00216060Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT07623460Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
NCT03547999A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
NCT03317158Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT02581059Efficacy of Ginseng for Patients on Regorafenib
NCT03871153Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
NCT04848337Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05928806Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT03783936Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
NCT00367601Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT05956041Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
NCT01524991First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
NCT02581215Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
NCT05502315Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT00216138Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
NCT00235235A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
NCT03396471Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
NCT00417248Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
NCT00216021Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
NCT03737123Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT03099564Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
NCT00859339Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
NCT04849364Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT02549209Pembro/Carbo/Taxol in Endometrial Cancer